Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03106779 · OUTCOME

Trough Plasma Concentrations for Asciminib

Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs · Source last updated 2026-08-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
ng/mL
Interval / dispersion
Full Range
Time frame
Week 2 Day 1 at: 0hr (pre-dose), 0.5hr, 1hr, 2hr, 3hr, 4hr, 6hr, 8hr & 12hr post-dose

What was measured

Measured concentration at the end of a dosing interval at steady state (taken directly before next administration)

Analysis population: Participants in the Pharmacokinetic analysis set (PAS) with an available value for the outcome measure. PAS included all participants who provided at least one evaluable PK concentration of asciminib.

Groups in this outcome

Asciminib

Participants randomized to asciminib 40mg BID

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Asciminib14

Reported measurements

Source class 1
Values in ng/mL · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Asciminib238Not reported145551Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        145
        upper Limit
        551
        value
        238
denoms
  1. counts
    1. group Id
      OG000
      value
      14
    units
    Participants
description
Measured concentration at the end of a dosing interval at steady state (taken directly before next administration)
dispersion Type
Full Range
groups
  1. description
    Participants randomized to asciminib 40mg BID
    id
    OG000
    title
    Asciminib
param Type
MEDIAN
population Description
Participants in the Pharmacokinetic analysis set (PAS) with an available value for the outcome measure. PAS included all participants who provided at least one evaluable PK concentration of asciminib.
reporting Status
POSTED
time Frame
Week 2 Day 1 at: 0hr (pre-dose), 0.5hr, 1hr, 2hr, 3hr, 4hr, 6hr, 8hr & 12hr post-dose
title
Trough Plasma Concentrations for Asciminib
type
SECONDARY
unit Of Measure
ng/mL

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice